Literature DB >> 8683220

Three new cytotoxic T cell epitopes identified within the hepatitis C virus nucleoprotein.

T Kaneko1, I Nakamura, H Kita, K Hiroishi, T Moriyama, M Imawari.   

Abstract

Cytotoxic T lymphocytes (CTLs) may play a role in host defence against hepatitis C virus (HCV) infection, and HCV-specific CTL epitopes may be included in vaccines to induce protective CTLs. We identified three new epitopes within the HCV nucleoprotein recognized by CTLs. HCV nucleoprotein residues 28-37 are the minimal epitope recognized by CTLs in association with the class I human leukocyte antigen B60, and epitopes in HCV nucleoprotein residues 111-130 and 161-180 are both recognized by CTLs in association with the class II human leukocyte antigen DRBI*08032.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8683220     DOI: 10.1099/0022-1317-77-6-1305

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  12 in total

1.  Identification of the epitopes on HCV core protein recognized by HLA-A2 restricted cytotoxic T lymphocytes.

Authors:  H C Zhou; D Z Xu; X P Wang; J X Zhang; Y Huang; Y P Yan; Y Zhu; B Q Jin
Journal:  World J Gastroenterol       Date:  2001-08       Impact factor: 5.742

2.  Detection of diverse hepatitis C virus (HCV)-specific cytotoxic T lymphocytes in peripheral blood of infected persons by screening for responses to all translated proteins of HCV.

Authors:  D K Wong; D D Dudley; P B Dohrenwend; G M Lauer; R T Chung; D L Thomas; B D Walker
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 3.  Cellular immune responses against hepatitis C virus: the evidence base 2002.

Authors:  S Ward; G Lauer; R Isba; B Walker; P Klenerman
Journal:  Clin Exp Immunol       Date:  2002-05       Impact factor: 4.330

4.  Identification of dominant optimal HLA-B60- and HLA-B61-restricted cytotoxic T-lymphocyte (CTL) epitopes: rapid characterization of CTL responses by enzyme-linked immunospot assay.

Authors:  M A Altfeld; A Trocha; R L Eldridge; E S Rosenberg; M N Phillips; M M Addo; R P Sekaly; S A Kalams; S A Burchett; K McIntosh; B D Walker; P J Goulder
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

5.  Cellular immune responses in seronegative sexual contacts of acute hepatitis C patients.

Authors:  Sanaa M Kamal; Ashraf Amin; Mohamed Madwar; Camilla S Graham; Qi He; Ahmed Al Tawil; Jens Rasenack; Tatsunori Nakano; Betty Robertson; Alaa Ismail; Margaret James Koziel
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

6.  Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus.

Authors:  M E Major; K Mihalik; J Fernandez; J Seidman; D Kleiner; A A Kolykhalov; C M Rice; S M Feinstone
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

7.  Comprehensive analysis of CD8(+)-T-cell responses against hepatitis C virus reveals multiple unpredicted specificities.

Authors:  Georg M Lauer; Kei Ouchi; Raymond T Chung; Tam N Nguyen; Cheryl L Day; Deborah R Purkis; Markus Reiser; Arthur Y Kim; Michaela Lucas; Paul Klenerman; Bruce D Walker
Journal:  J Virol       Date:  2002-06       Impact factor: 5.103

8.  Comparative features of hepatitis C virus infection in humans and chimpanzees.

Authors:  C M Walker
Journal:  Springer Semin Immunopathol       Date:  1997

9.  Immune response of cytotoxic T lymphocytes and possibility of vaccine development for hepatitis C virus infection.

Authors:  Kazumasa Hiroishi; Junichi Eguchi; Shigeaki Ishii; Ayako Hiraide; Masashi Sakaki; Hiroyoshi Doi; Risa Omori; Michio Imawari
Journal:  J Biomed Biotechnol       Date:  2010-05-20

10.  CD28-negative CD8-positive cytotoxic T lymphocytes mediate hepatocellular damage in hepatitis C virus infection.

Authors:  Kazutaka Kurokohchi; Tsutomu Masaki; Keiji Arima; Yoshiaki Miyauchi; Toshiharu Funaki; Hirohito Yoneyama; Shuhei Yoshida; Akihiro Deguchi; Seiji Nakai; Seishiro Watanabe; Shigeki Kuriyama
Journal:  J Clin Immunol       Date:  2003-11       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.